RNS Number : 3099T Renalytix PLC 14 November 2023 Renalytix plc ("Renalytix" or the "Company") Renalytix Reports Financial Results for First Quarter of Fiscal Year 2024 LONDON and SALT LAKE CITY , November 14, 2023 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial
RNS Number : 5522S Renalytix PLC 07 November 2023 Renalytix plc ("Renalytix" or the "Company") Renalytix to Report Financial Results for First Quarter Fiscal Year 2024 on November 14 LONDON and SALT LAKE CITY , November 7, 2023 -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that it
RNS Number : 7470R Renalytix PLC 30 October 2023 Renalytix plc ("Renalytix" or the "Company") Announcement of AGM and Publication of Annual Report 2023 LONDON and SALT LAKE CITY, UT October 30, 2023 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that its Annual General Meeting
RNS Number : 0376R Renalytix PLC 24 October 2023 Renalytix plc ("Renalytix" or the "Company") Directorate change LONDON and SALT LAKE CITY - October 24, 2023 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX) , the first company to commercialize an FDA authorized artificial intelligence (AI)
RNS Number : 3030Q Renalytix PLC 17 October 2023 Renalytix plc ("Renalytix" or the "Company") Issue of Shares LONDON and SALT LAKE CITY - October 17, 2023 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX) , announces the repayment of $1.06 million of the Company's convertible bond, further
RNS Number : 8892O Renalytix PLC 06 October 2023 Renalytix plc ("Renalytix" or the "Company") US Patent Office Allows Patent Claims for Intellectual Property Exclusively Licensed to Renalytix LONDON and SALT LAKE CITY - October 6, 2023 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX), the
RNS Number : 5660O Renalytix PLC 03 October 2023 Renalytix plc ("Renalytix" or the "Company") Issue of Shares LONDON and SALT LAKE CITY , October 3, 2023 -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that under the Company's Employee Share Purchase Plan (the "ESPP"), 75,328 new
RNS Number : 4486O Renalytix PLC 03 October 2023 THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED IN ARTICLE 7 OF MAR. THE PERSON RESPONSIBLE FOR ARRANGING THE RELEASE OF THIS ANNOUNCEMENT ON BEHALF OF RENALYTIX IS JAMES MCCULLOUGH , CEO. Renalytix plc ("Renalytix" or the "Company")
RNS Number : 9254N Renalytix PLC 28 September 2023 Renalytix plc ("Renalytix" or the "Company") Renalytix Reports Full Year Fiscal 2023 Results LONDON and SALT LAKE CITY , September 28, 2023 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics
RNS Number : 4406N Renalytix PLC 25 September 2023 Renalytix plc ("Renalytix" or the "Company") Renalytix to Report Financial Results for Fourth Quarter and Full Year Fiscal 2023 on September 28 LONDON and SALT LAKE CITY , September 25, 2023 -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX)